☆ 4.7 Editorial Material

MEK-ing the Most of It: Strategies to Co-target Gαq and MAPK in Uveal Melanoma

CLINICAL CANCER RESEARCH (2021)

Combined Inhibition of Gαq and MEK Enhances Therapeutic Efficacy in Uveal Melanoma

Tyler D. Hitchman et al.

Summary: The study found that the combination of Gα(q) and MEK inhibition showed promising therapeutic potential in treating melanoma, suggesting an improved therapeutic strategy for targeting Gα(q) in uveal melanoma.

CLINICAL CANCER RESEARCH (2021)

添加到收藏夹

Article Oncology

HDAC Inhibition Enhances the In Vivo Efficacy of MEK Inhibitor Therapy in Uveal Melanoma

Fernanda Faiao-Flores et al.

CLINICAL CANCER RESEARCH (2019)

添加到收藏夹

Article Medicine, General & Internal

Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma

C. Robert et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

添加到收藏夹

Article Oncology

Selumetinib in Combination With Dacarbazine in Patients With Metastatic Uveal Melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT)

Richard D. Carvajal et al.

JOURNAL OF CLINICAL ONCOLOGY (2018)

添加到收藏夹

Review Oncology

Dysregulated GPCR Signaling and Therapeutic Options in Uveal Melanoma

Vivian Chua et al.

MOLECULAR CANCER RESEARCH (2017)

添加到收藏夹

MEK-ing the Most of It: Strategies to Co-target Gαq and MAPK in Uveal Melanoma

相关参考文献

Combined Inhibition of Gαq and MEK Enhances Therapeutic Efficacy in Uveal Melanoma

HDAC Inhibition Enhances the In Vivo Efficacy of MEK Inhibitor Therapy in Uveal Melanoma

Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma

Selumetinib in Combination With Dacarbazine in Patients With Metastatic Uveal Melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT)

Dysregulated GPCR Signaling and Therapeutic Options in Uveal Melanoma

导出引文

分享论文